Today’s Rating On Watch: Avacta Group PLC (LON:AVCT) Stock “Corporate” Rating Kept at finnCap; The Target Price per Share is Set to GBX 200.00

November 23, 2016 - By Marguerite Chambers

Avacta Group PLC (LON:AVCT) Rating

Equities researchers at finnCap have GBX 200.00 target on Avacta Group PLC (LON:AVCT). finnCap’s target gives a potential upside of 125.99% from the company’s last price. The rating was released in an analyst report on 23 November.

Avacta Group Plc (LON:AVCT) Ratings Coverage

Out of 2 analysts covering Avacta Group PLC (LON:AVCT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 200 is the highest target while GBX 1.60 is the lowest. The GBX 180 average target is 103.39% above today’s (GBX 88.5) stock price. Avacta Group PLC has been the topic of 9 analyst reports since October 26, 2015 according to StockzIntelligence Inc. Numis Securities maintained Avacta Group Plc (LON:AVCT) on Wednesday, August 3 with “Buy” rating. The firm has “Corporate” rating by FinnCap given on Wednesday, November 23. FinnCap maintained the stock with “Corporate” rating in Tuesday, November 1 report. The stock has “Corporate” rating given by FinnCap on Monday, October 17. The stock of Avacta Group Plc (LON:AVCT) has “Buy” rating given on Monday, August 1 by Numis Securities. Numis Securities reinitiated Avacta Group Plc (LON:AVCT) on Monday, April 25 with “Buy” rating. The firm has “Corporate” rating by FinnCap given on Thursday, September 22.

It is down 21.33% since April 25, 2016 and is downtrending. It has underperformed by 26.66% the S&P500.

Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The company has a market cap of 61.56 million GBP. The Company’s divisions include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. It currently has negative earnings. The Company’s in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies.

More news for Avacta Group Plc (LON:AVCT) were recently published by:, which released: “Avacta Group Plc (AVCT.L)” on January 07, 2014. Fool.Co.Uk‘s article titled: “Avacta Group Plc Jumps After Transformational Moderna Therapeutics Deal” and published on May 18, 2015 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News